Is Scholar Rock Holding Corp (SRRK) Stock About to Get Hot Monday?

Overall market sentiment has been high on Scholar Rock Holding Corp (SRRK) stock lately. SRRK receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Scholar Rock Holding Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SRRK!

See Full SRRK Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With SRRK Stock Today?

Scholar Rock Holding Corp (SRRK) stock is down -2.56% while the S&P 500 has risen 0.46% as of 12:31 PM on Monday, Nov 20. SRRK has fallen -$0.31 from the previous closing price of $12.13 on volume of 335,890 shares. Over the past year the S&P 500 is higher by 14.81% while SRRK has risen 48.87%. SRRK lost -$1.99 per share in the over the last 12 months. To screen for more stocks like Scholar Rock Holding Corp click here.

More About Scholar Rock Holding Corp

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Click Here to get the full Stock Report for Scholar Rock Holding Corp stock.